

miR-141-3p is a key negative regulator of the EGFR pathway in osteosarcoma

Jiashi Wang
Guangbin Wang
Bin Li
Chuang Qiu
Ming He

Department of Orthopedic Surgery,
Shengjing Hospital of China Medical
University, Shenyang, Liaoning,
People's Republic of China

Background: Many studies have used miRNA to modulate osteosarcoma development by regulating protein expression, and these studies showed that the expression of EGFR is increased in osteosarcoma.

Methods: Western blot, real-time PCR and immunohistochemical were used to detect the expression of EGFR and miR-141 in osteosarcoma tissues and cells. The correlation between miR-141 and the grading of osteosarcoma and the correlation with the survival time of the patients were analyzed. After predicting the target effect of miR-141 on EGFR by miRDB, correlation analysis was used to analyze the correlation between miR-141 and EGFR. Luciferase reporter gene, western blot and real-time PCR were used to detect the targeting effect of miR-141 on EGFR. Then we detected the effect of miR-141 on proliferation by MTT and PI staining. The effect of miR-141 on cell apoptosis was detected by Hoechst33258 and AV-PI staining, and the effect of miR-141 on cell migration was detected by Transwell. The regulatory effects of miR-141 on related proteins were detected by western blot and real-time PCR. Finally, we transfected EGFR and EGFR DEL (mutation with miR-141 binding site) in osteosarcoma cells, and detected the effects of miR-141 on cell proliferation, apoptosis, migration and related proteins.

Results: The expression of miR-141-3p was negatively correlated with the expression of EGFR in osteosarcoma. The overexpression of miR-141-3p was not only closely related to the classification and size of the osteosarcoma but also had a negative effect on the growth and migration of the osteosarcoma through negative regulation of the expression of EGFR. MiR-141 can inhibit the growth and metastasis of osteosarcoma cells by targeting EGFR and affecting its downstream pathway proteins.

Conclusion: Our study provides miR-141-3p may be a new theoretical basis for the treatment of osteosarcoma.

Keywords: EGFR, osteosarcoma, prognosis, growth, migration

Introduction

Although examinations, surgery, and chemotherapy are continuously improving, the 5-year survival rate of osteosarcoma is still below 60%.¹ Osteosarcoma usually has a complex genome mutation, which was proven by many studies at the molecular level.²

Molecular target therapy is a particularly effective method for the treatment of recurrent cancer. Epidermal growth factor receptor (EGFR) is one of 4 members of the HER family of receptor tyrosine kinases.³ As EGFR can activate many signaling cascades, such as the PI3K/Akt, and Jak/STAT pathways, it plays an important role in the regulation of cell proliferation, survival, and metastasis.

MicroRNA (miRNA) is the key regulator of gene expression in many species. More than 60% of human protein coding genes are downregulated by miRNAs.⁴ It has been reported that the expression of miRNA in osteosarcoma is abnormal.⁵ Studies have

Correspondence: Ming He
Department of Orthopedic Surgery,
Shengjing Hospital of China Medical
University, 36 Sanhao Street,
Heping District, Shenyang 110004,
People's Republic of China
Tel +86 249 6615
Fax +86 24 966 153 3111
Email topheming56@163.com

found that miR-29 can suppress proliferation and migration via the modulation of vascular endothelial growth factor in osteosarcoma *in vitro*.⁶ In human osteosarcoma cells, apoptosis can be promoted by miR-199a-3p and miR-34a.⁷ miR-135b can target c-Myc in osteosarcoma and suppress the occurrence and development of cancer.⁸ miR-143 can suppress osteosarcoma metastasis by regulating matrix metalloproteinase (MMP)-13 expression *in vitro*.⁹ All of these data proved that miRNA plays a very important role in the development of osteosarcoma. miRNA may be a therapeutic target in the treatment of osteosarcoma.

miR-141-3p has been reported to inhibit the occurrence and development of many kinds of tumors.¹⁰ It can suppress the migration and invasion of HCC cells.¹¹ However, there have been no reports on the expression and function of miR-141-3p in osteosarcoma.

In this study, we examined the expression of miR-141-3p and EGFR in osteosarcoma and analyzed the correlation between them. It was found that miR-141-3p can inhibit the growth of osteosarcoma cells by regulating the expression of the EGFR protein.

Materials and methods

Patients and tissue samples

Thirty-two patients with primary osteosarcoma hospitalized in Shengjing Hospital between 2010 and 2015 were retrospectively analyzed. All patient information is shown in Table 1. The treatment details were as previously described.¹² All patients reviewed the methods and significance of the study and provided written informed consent. The project was approved by the ethics committee for medical science research of Shengjing Hospital (R20110711). All osteosarcoma tissues were pathologically confirmed to be osteosarcoma. Before obtaining the tissue, the patient had not undergone any chemotherapy, radiotherapy, or tumor-related drug therapy.

Table 1 The relationship between miR-141-3p and osteosarcoma

Parameters	Description	No of patient	miR-141 expression		Chi-squared	P-value
			Low	High		
Gender	Male	16	10	6	0.581	0.446
	Female	16	12	4		
Age (years)	<40	22	14	8	0.134	0.714
	≥40	10	8	2		
TNM grade	I	3	2	1	8.301	0.040*
	II	20	17	3		
	III	8	3	5		
	IV	1	0	1		

Note: *P<0.05.

Western blot analyses

To determine the expression of protein in tissues and cells, Western blot was used; whole cell extracts (lysate) were prepared from 1×10^6 cells or tissues in lysis buffer. Approximately 60 µg of the protein was resolved on 10% sodium dodecyl sulfate-polyacrylamide gels. After electrophoresis, the proteins were electrotransferred to nitrocellulose filters, and the membrane (Amersham, Shanghai, China) was blocked with 5% nonfat dry milk in tris-buffered saline with Tween 20 for 1 hour at room temperature and incubated with primary antibody. Target proteins were probed with specific antibodies – EGFR (1:1,000), Akt (1:1,000), Akt^{p-Ser473} (1:1,000), cyclin D1 (1:1,000), bcl-2 (1:1,000), bax (1:1,000), glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (1:3,000) and horseradish peroxidase-rabbit secondary antibody (1:5,000) (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA). To ensure equal loading, gels were stripped and reprobed with antibodies against GAPDH. All polyvinylidene difluoride membranes were detected by enhanced chemiluminescence (Pierce Technology, Beijing, China).

Real-time polymerase chain reaction (RT-PCR)

RT-PCR was used to detect the expression of mRNA in tissues and cells. Total RNA was extracted from tissues and MG63 cells by TRIzol (Thermo Fisher Scientific, Waltham, MA, USA) which was used to overhang cells or homogenate tissue. Add chloroform to mix and centrifuge and leave the supernatant. Add isopropanol and remove the supernatant by centrifugation. RNA was obtained after the use of ethanol to clean. The expression of miR-141-3p was detected with a Stem-Loop RT-PCR assay as previously reported.^{13,14} Primer sequences were synthesized as shown in Table 2.

All the reactions were carried out as described previously.¹⁵

Immunohistochemical staining

Immunohistochemical staining was used to detect the expression of EGFR in tissues. All osteosarcoma patients fulfilled the diagnostic criteria for osteosarcoma as defined in the World Health Organization classification. We used grade, tumor, metastasis (GTM) classification to evaluate osteosarcoma. G refers to the benign and malignant degree of the tumor. T refers to the range of tumor invasion. M refers to regional or distant metastasis. Tissues were fixed with 4% paraformaldehyde, permeabilized for 10 minutes with PBS containing 0.1% Triton X-100 and blocked with 1% bovine serum albumin. Immunostaining was performed

Table 2 Primers for real-time polymerase chain reaction

Name	Forward primer (5'→3')	Reverse primer (5'→3')
miR-141	ACACTCCAGCTGGGCATCTCCAG	CTCAACTGGTGTCTGGAGTCGGC
U6	CTCGCTTCGGCAGCACA	AATTCAGTTGAGTCCAAC
EGFR	CCTACGGGCCAGGAAATGAG	AACGCTTCACGAATTTGCGT
Akt	GAAGGACGGGAGCAGGC	CCCAGCTGAAACTCTGACG
Cyclin D1	CCGAGGAGCTGCTGCAATGGAG	AAGGTGCGTTCGATGACAGT
Bcl-2	GGTGAAGTGGGGGAGGATTG	GAAATCGTGC GGGGTCAATTGC
Bax	AGCTGAGCGAGTGTCTCAAG	GCGAGGCATGTTGACTTCAC
GAPDH	CTCTGCTCCTCTGTTCGAC	GTCCAATGTCCAGCCCATGA
		GCGCCCAATACGACCAAATC

Abbreviations: EGFR, epidermal growth factor receptor; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.

using the appropriate primary (EGFR, 1:800) and secondary antibodies, and images were acquired using an Olympus fluorescence microscope. Immunohistochemical results were judged by HSCORE (histological score).¹⁶ Immunostaining intensity was estimated for each tissue core as follows: 1, weak; 2, moderate; or 3, strong.

Survival function

We use the Kaplan–Meier method to compute survival function. The abscissa is the survival time. The ordinate is the size of the survival function. Patients with a high expression of miR-141-3p in osteosarcoma tissues.

Dual luciferase reporter assay

Dual luciferase reporter assay was used to detect whether there is a direct binding site between miR-141-3p and EGFR. The EGFR 3' untranslated region (3'-UTR) was PCR amplified and cloned into the pMIR-REPORT™ vector (Ambion, Shanghai, China). The primers were as follows: EGFR-WT, F: 5'-CGAATGGGCCTAAGATCCCG-3', R: 5'-CGGUCGUCUCGUCAGUC-3', EGFR-DEL (Mutation of the loci of EGFR and miR-141-3p), F: 5'-CGAATGGGCCTAAGATCCCG-3', R: 5'-CUCGGAGAGGGAC-3'. pMIR-REPORT™-β GAL (control), miR-141-3p mimic and miR-141-3p antisense (AS) with EGFR-WT or EGFR-DEL were introduced into MG63 and HOS cells. After 36 hours, the luciferase activity was measured using the Dual Luciferase Reporter Assay System (Promega, Beijing, China) as described.¹⁷

Cell count

Cell count was used to detect the effect of miR-141-3p on cell proliferation. The cell count was also used to determine the quantity of cells after transfection with 0, 50, and 100 nm miR-141-3p mimic/inhibitor using a Malassez counting chamber. Cells were trypsinized from 6-well plates, and cells from each well were counted 3 times.

MTT assays

hFOB1.19 cells and human osteosarcoma cell lines HOS and MG-63 were obtained from the American Type Culture Collection (Manassas, VA, USA). MTT assay was used to detect the effect of miR-141-3p on cell proliferation. Cells were seeded in 96-well plates; 2,000 cells in 200 μL of media in each well and incubated overnight at 37°C in a humidified 5% CO₂ incubator. On the following day, cells were transfected with 100 nm miR-141-3p mimic (UAAC ACUGUCUGGUAAGAUGG), 100 nm miR-141-3p inhibitor (CCAUCUUUACCAGACAGUGUUA) or control. The MTT assay was used to measure cell proliferation with a microplate reader (BIO-RAD, Beijing, China).

Hoechst 33258 assay

Hoechst 33258 assay was used to detect the effect of miR-141-3p on cell apoptosis. After transfection for 24 hours, cells were washed twice with PBS, incubated with 10 μg/mL Hoechst 33258 for 5 minutes at room temperature, and washed with PBS 3 times. Cells were observed with a fluorescence microscope.

Annexin V (AV)–propidium iodide (PI) assay

AV-PI assay was used to detect the effect of miR-141-3p on cell apoptosis. The cells were washed twice with cold PBS, then resuspended with binding buffer at a concentration of 1×10⁶ cells/mL. Then, 5 μL of ANNEXIN-V-fluorescein isothiocyanate and 10 μL of PI were added. The cells were incubated in the dark at room temperature for 15 minutes. Finally, 400 μL binding buffer was added to each tube, and the apoptosis rate was measured by flow cytometry within 1 hour.

Transwell Migration assay

Transwell was used to detect the effect of miR-141-3p on cell metastasis. After transfection, 1×10⁵ cells in serum-free media were seeded in transwell chambers, and then a transwell assay

was performed. Eight hours later, cells were fixed with 4% paraformaldehyde and stained with 0.4% trypan blue.

Statistical analysis

Experiments were repeated 3 times. Analysis of variance models were used to analyze the data for each group separately.

Ethics approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of

the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Results

The expression of EGFR and miR-141-3p in osteosarcoma tissues

To detect the expression of EGFR in osteosarcoma, tumor tissues and adjacent normal tissues were obtained from 32 patients and analyzed by Western blot (17 paired) and RT-PCR (32 paired) (Figure 1A and B). The results




Figure 1 (Continued)




Figure 1 The expression of EGFR and miR-141-3p in osteosarcoma tissues.

Notes: (A, B) The protein and mRNA levels of EGFR expression in 32 samples of osteosarcoma tissues (os) and adjacent tissues (n) (C). The expression of EGFR was higher in the osteosarcoma tissues than in the adjacent tissues. Data are shown as the mean \pm SEM. $**P < 0.01$ vs adjacent tissues. (C) The protein level of EGFR expression in osteosarcoma tissues. The expression of EGFR increased with an increase in the GTM grade. (D) The levels of miR-141-3p were detected by real-time PCR. There was a lower expression of miR-141-3p in osteosarcoma tissues. Data are shown as the mean \pm SEM. $**P < 0.01$ vs adjacent tissues. (E) The expression of miR-141-3p was related to the survival of osteosarcoma. (F) The expression of miR-141-3p in cells. Data are shown as the mean \pm SEM. $**P < 0.01$ vs hFOB1.19 cells. (G, H) The expression of miR-141-3p in cells. $**P < 0.01$ vs hFOB1.19 cells.

Abbreviations: EGFR, epidermal growth factor receptor; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GTM, grade, tumor, metastasis; PCR, polymerase chain reaction; SEM, standard error of the mean.

showed that the expression of EGFR in tumor tissues was higher than that in the adjacent tissues. At the same time, the expression of EGFR in osteosarcoma was detected by immunohistochemistry (Figure 1C). The results showed that EGFR was positively correlated with the GTM grade of osteosarcoma. Furthermore, the expression of miR-141-3p in osteosarcoma was detected by RT-PCR assay, which showed that the expression of miR-141-3p in osteosarcoma was low (Figure 1D). Patients with higher miR-141-3p expression had better prognosis than patients with low miR-141-3p expression (Figure 1E). We examined the correlation between miR-141-3p and osteosarcoma, and the results showed that miR-141-3p was associated with the classification of osteosarcoma (Table 1). We found that the expression of miR-141-3p in osteosarcoma cell lines was low according to RT-PCR (Figure 1F). The expression of EGFR in MG63 and HOS cells was higher than that of hFOB1.19 cells (Figure 1G and H).

miR-141-3p can inhibit the expression of EGFR

The experiment showed that miR-141-3p can inhibit the expression of multiple proteins by using the miRDB tool (a site for miRNA target prediction and functional annotation of miRNA and target genes) (Figure 2A). Moreover, miR-141-3p can be targeted to the 3'-UTR region with EGFR (Figure 2B). We analyzed the results of the RT-PCR, and the expression of miR-141-3p was negatively correlated with the expression of EGFR in the osteosarcoma tissues (Figure 2C). The luciferase reporter assay was carried out to determine whether EGFR is a potential target gene of miR-141-3p (Figure 2D). The results showed

that co-transfection of EGFR-WT with miR-141-3p produced lower luciferase activity in MG63 and HOS cells. However, no significant variation was observed in the cells co-transfected with EGFR-DEL or miR-141-3p AS. Western blot and RT-PCR were used to further validate the interaction of the miRNA-target (Figure 2E–L). The results showed that the content of EGFR decreased when miR-141-3p was overexpressed in MG63 cells and that the miR-141-3p overexpression and low expression cell lines were successfully constructed. When miR-141-3p was inhibited in MG63 cells, the expression of EGFR was significantly increased.

miR-141-3p inhibits the proliferation of osteosarcoma cells

We examined the effects of different concentrations of miR-141 for MG63 and HOS cells. The results showed that the inhibitory effect of the transfection concentration of 100 nm on cells was obvious, and could be used for a follow-up experiment (Figure 3A and B). MTT assays showed that the overexpression of miR-141-3p can inhibit the proliferation of osteosarcoma cells (Figure 3C and D). Furthermore, the results showed that miR-141-3p can inhibit Akt^{p-Ser473} and cyclin D1 and thus played a role in inhibiting cell proliferation (Figure 3E–H). The experimental results showed that miR-141-3p can affect the proliferation of cells by affecting the EGFR/Akt signaling pathway.

miR-141-3p promotes the apoptosis of osteosarcoma cells

The effect of miR-141-3p on the apoptosis of osteosarcoma cells was examined by Hoechst 33258 assay




Figure 2 (Continued)




Figure 2 miR-141-3p can inhibit the expression of EGFR.

Notes: (A) Site prediction showed that miR-141-3p can target several proteins. (B) miRDB predicted that miR-141-3p could specifically combine with EGFR. (C) The expression of miR-141-3p was negatively correlated with the expression of EGFR. (D) Luciferase reporter assays of the interaction between miR-141-3p and the EGFR 3'-UTR. Data are shown as the mean \pm SEM. $**P < 0.01$ vs EGFR group. (E–H) Western blot and real-time PCR showed that when the miR-141-3p was overexpressed/repressed, the expression of EGFR was downregulated/upregulated in MG63 cells. Data are shown as the mean \pm SEM. $**P < 0.01$ vs control group. (I–L) Western blot and real-time PCR showed that when the miR-141-3p was overexpressed/repressed, the expression of EGFR was downregulated/upregulated in HOS cells. Data are shown as the mean \pm SEM. $**P < 0.01$ vs the control group.

Abbreviations: EGFR, epidermal growth factor receptor; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; PCR, polymerase chain reaction; SEM, standard error of the mean; con, control.

(Figure 4A and B). The results showed that miR-141-3p could promote the apoptosis of osteosarcoma cells. In the AV-PI staining experiment, the Q4 region represents apoptotic cells, and apoptotic cells increase when miR-141-3p expression is increased (Figure 4C and D). At both the protein and RNA levels, miR-141-3p can promote the expression of bax and inhibit the expression of Bcl-2 (Figure 4E–H).

miR-141-3p inhibits the migration of osteosarcoma cells

Transwell assay showed that miR-141-3p could inhibit the migration of osteosarcoma cells (Figure 5A–D). miR-141-3p can inhibit the expression of MMP2, which was proven by Western blot and RT-PCR (Figure 5E–H).

miR-141-3p inhibits the growth and migration of MG63 cells

EGFR and EGFR-DEL plasmid were transfected into overexpressed miR-141-3p cells. The MTT assay results confirmed that the inhibitory effect of miR-141-3p on MG63 was weakened after the loss of the specific miR-141-3p combining region in EGFR (Figure 6A). Then, the effect of miR-141-3p on apoptosis and metastasis was detected by Hoechst 33258, AV-PI, and transwell assays (Figure 6B–D). The results revealed that miR-141-3p could not promote cell apoptosis or inhibit migration by suppressing EGFR-DEL. Next, the inhibitory effect of miR-141-3p on the pathway was detected by Western blot and RT-PCR. The regulatory effect of miR-141-3p on EGFR downstream proteins was




Figure 3 (Continued)




Figure 3 miR-141-3p inhibits the proliferation of osteosarcoma cells. (A, B) After overexpressing or inhibiting the expression of miR-141-3p, cell counting was performed for the same MG63 and HOS clones. Data are shown as mean \pm SEM. $**P < 0.01$ vs control group. (C, D) After overexpressing or inhibiting the expression of miR-141-3p, cell growth was detected by MTT assay. Data are shown as the mean \pm SEM. $**P < 0.01$ vs control group. (E–H) MG63 cells were overexpressed/downregulated with miR-141-3p, and the indicated proteins and RNA levels were detected by Western blot and real-time PCR. Data are shown as the mean \pm SEM. $**P < 0.01$.

Abbreviations: EGFR, epidermal growth factor receptor; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; PCR, polymerase chain reaction; SEM, standard error of the mean; con, control.

crippled when EGFR lost its specific miR-141-3p combining region (Figure 6E and F).

Discussion

As a kind of small, endogenous and noncoding RNA, miRNA can combine with the mRNA 3'-UTR, resulting in the inhibition of mRNA translation or the degradation

of mRNA.¹⁸ A large number of studies indicated that the abnormal expression of mRNA is closely related to the occurrence and development of many tumors. To date, many studies have reported that the abnormal expression of miRNA is involved in the occurrence and development of osteosarcoma. It is closely related to the prognosis of osteosarcoma. miR-141-3p is a member of the miR-200 family,




Figure 4 (Continued)




Figure 4 miR-141-3p promotes the apoptosis of osteosarcoma cells.

Notes: (A, B) MG63 cells and HOS cells were overexpressed or inhibited with miR-141-3p; 24 hours later, Hoechst 33258 staining was performed. (C, D) MG63 cells and HOS cells were overexpressed or inhibited with miR-141-3p; 24 hours later, AV-PI assay was performed. Q4 means for apoptosis cells. (E–H) MG63 cells were overexpressed/downregulated with miR-141-3p, and the indicated proteins and RNA levels were detected by Western blot and real-time PCR. Data are shown as mean \pm SEM. $**P < 0.01$ vs the control group.

Abbreviations: AV, annexin V; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; PCR, polymerase chain reaction; PI, propidium iodide; SEM, standard error of the mean; con, control.




Figure 5 miR-141-3p inhibits the migration of osteosarcoma cells.

Notes: (A–D) MG63 cells and HOS cells were overexpressed or inhibited with miR-141-3p; 24 hours later, transwell assay was performed. Data are shown as mean \pm SEM. $^{***}P<0.01$ vs the control group. (E–H) MG63 cells were overexpressed/downregulated with miR-141-3p, and the indicated proteins and RNA levels were detected by Western blot and real-time PCR. Data are shown as the mean \pm SEM. $^{**}P<0.01$ vs the control group.

Abbreviations: GAPDH, glyceraldehyde-3-phosphate dehydrogenase; MMP, matrix metalloproteinase; PCR, polymerase chain reaction; SEM, standard error of the mean; con, control.

which is thought to be abnormal in a variety of tumors. It can affect the biological function of the tumor cells by regulating the expression of proteins. miR-141-3p has been found to be highly expressed in various cancers, such as ovarian cancer,¹⁹ colon cancer,²⁰ nasopharyngeal carcinoma,¹¹ prostate cancer,²¹ gastric cancer,²² and breast cancer.²³ Experiments showed that miR-141-3p can effectively predict the prognosis of HCC patients. The miR-141-3p/TAZ axis can inhibit the proliferation, migration, and invasion of gastric cancer cells.²⁴ The high expression of miR-141-3p was associated with a shorter overall survival of non-small cell lung cancer patients with adenocarcinoma through angiogenesis

and mesenchymal epithelial transition factor.²⁵ miR-141-3p is upregulated in the serum of prostate cancer patients, and it may be a useful potential biomarker for the diagnosis of metastatic prostate cancer.²⁶

The present study indicates that the EGFR inhibitor ZD6474 has a certain effect on the treatment of osteosarcoma.²⁷ Another report showed that the anti-EGFR antibody cetuximab enhanced the cytolytic activity of natural killer cells toward osteosarcoma cells.²⁸ However, whether the expression of EGFR in osteosarcoma plays a significant role in the occurrence and development of osteosarcoma is still controversial.²⁹




Figure 6 (Continued)




Figure 6 miR-141-3p inhibits the growth and migration of MG63 cells.

Notes: (A) MG63 cells were overexpressed with miR-141-3p, and then EGFR-FL or EGFR-DEL was transferred into cells. After that, the MTT assay was performed. Data are shown as the mean \pm SEM. (B) MG63 cells were overexpressed with miR-141-3p, and then EGFR-FL or EGFR-DEL was transferred into cells. After that, Hoechst 33258 staining was performed. (C) MG63 cells were overexpressed with miR-141-3p, and then EGFR-FL or EGFR-DEL was transferred into cells. After that, AV-PI assay was performed. (D) MG63 cells were overexpressed with miR-141-3p, and then EGFR-FL or EGFR-DEL was transferred into cells. After that, the transwell assay was performed. Data are shown as the mean \pm SEM. $P < 0.01$. (E, F) After overexpressing miR-141-3p, EGFR-FL or EGFR-DEL was transferred into cells. The indicated proteins and RNA levels were detected by Western blot and real-time PCR. Data are shown as the mean \pm SEM. $^{**}P < 0.01$ miR-141 group vs the control group.

Abbreviations: EGFR, epidermal growth factor receptor; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; MMP, matrix metalloproteinase; PCR, polymerase chain reaction; SEM, standard error of the mean.

In our study, we found that miR-141-3p was expressed at low levels in osteosarcoma, and there was a certain correlation between the expression of miR-141-3p and the survival rate of patients. At the same time, the expression of miR-141-3p was negatively correlated with the expression of EGFR. miR-141-3p can inhibit the expression of EGFR and the growth and migration of osteosarcoma by regulating the expression of EGFR.

In conclusion, our study showed that miR-141-3p can inhibit the occurrence and development of osteosarcoma by regulating the expression of EGFR. This suggests that miR-141-3p may play a specific role in the treatment of osteosarcoma.

Acknowledgment

All personnel who have contributed to this article are in the list of authors.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Vander Griend RA. Osteosarcoma and its variants. *Orthop Clin North Am*. 1996;27(3):575–581.

2. Meyer S, Reinhard H, Graf N, Püschel W, Ziegler K, Schneider G. The importance of conventional radiographs in the diagnosis of osteosarcoma. *Klin Padiatr*. 2002;214(2):58–61.
3. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. *Nat Rev Mol Cell Biol*. 2001;2(2):127–137.
4. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. *Genome Res*. 2009;19(1):92–105.
5. Shen L, Wang P, Yang J, Li X. MicroRNA-217 regulates WASF3 expression and suppresses tumor growth and metastasis in osteosarcoma. *PLoS One*. 2014;9(10):e109138.
6. Zhang K, Zhang C, Liu L, Zhou J. A key role of microRNA-29b in suppression of osteosarcoma cell proliferation and migration via modulation of VEGF. *Int J Clin Exp Pathol*. 2014;7(9):5701–5708.
7. Tian Y, Zhang YZ, Chen W. MicroRNA-199a-3p and microRNA-34a regulate apoptosis in human osteosarcoma cells. *Biosci Rep*. 2014;34(4):pii: e00132.
8. Liu Z, Zhang G, Li J, Liu J, Lv P. The tumor-suppressive microRNA-135b targets c-myc in osteosarcoma. *PLoS One*. 2014;9(7):e102621.
9. Osaki M, Takeshita F, Sugimoto Y, et al. MicroRNA-143 regulates human osteosarcoma metastasis by regulating matrix metalloproteinase-13 expression. *Mol Ther*. 2011;19(6):1123–1130.
10. Liu Y, Ding Y, Huang J, et al. MiR-141 suppresses the migration and invasion of HCC cells by targeting Tiam1. *PLoS One*. 2014;9(2):e88393.
11. Cheng H, Zhang L, Cogdell DE, et al. Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. *PLoS One*. 2011;6(3):e17745.
12. Feng D, Yang X, Liu T, et al. Osteosarcoma of the spine: surgical treatment and outcomes. *World J Surg Oncol*. 2013;11(1):89.
13. Feng J, Wang K, Liu X, Chen S, Chen J. The quantification of tomato microRNAs response to viral infection by stem-loop real-time RT-PCR. *Gene*. 2009;437(1–2):14–21.

14. Chen C, Ridzon DA, Broomer AJ, et al. Real-time quantification of microRNAs by stem-loop RT-PCR. *Nucleic Acids Res.* 2005; 33(20):e179.
15. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. *Nucleic Acids Res.* 2001;29(9):e45.
16. Thorarinsdottir HK, Santi M, McCarter R, et al. Protein expression of platelet-derived growth factor receptor correlates with malignant histology and PTEN with survival in childhood gliomas. *Clin Cancer Res.* 2008;14(11):3386–3394.
17. Cheng Z, Liu F, Wang G, Li Y, Zhang H, Li F. miR-133 is a key negative regulator of CDC42-PAK pathway in gastric cancer. *Cell Signal.* 2014;26(12):2667–2673.
18. Ventura A, Jacks T. MicroRNAs and cancer: short RNAs go a long way. *Cell.* 2009;136(4):586–591.
19. Iorio MV, Visone R, di Leva G, et al. MicroRNA signatures in human ovarian cancer. *Cancer Res.* 2007;67(18):8699–8707.
20. Schetter AJ, Leung SY, Sohn JJ, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. *JAMA.* 2008;299(4):425–436.
21. Zhang L, Deng T, Li X, et al. microRNA-141 is involved in a nasopharyngeal carcinoma-related genes network. *Carcinogenesis.* 2010; 31(4):559–566.
22. Du Y, Xu Y, Ding L, et al. Down-regulation of miR-141 in gastric cancer and its involvement in cell growth. *J Gastroenterol.* 2009; 44(6):556–561.
23. Gregory PA, Bert AG, Paterson EL, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. *Nat Cell Biol.* 2008;10(5):593–601.
24. Zuo QF, Zhang R, Li BS, et al. MicroRNA-141 inhibits tumor growth and metastasis in gastric cancer by directly targeting transcriptional co-activator with PDZ-binding motif, TAZ. *Cell Death Dis.* 2015;6:e1623.
25. Tejero R, Navarro A, Campayo M, et al. miR-141 and miR-200c as markers of overall survival in early stage non-small cell lung cancer adenocarcinoma. *PLoS One.* 2014;9(7):e101899.
26. Li Z, Ma YY, Wang J, et al. Exosomal microRNA-141 is upregulated in the serum of prostate cancer patients. *Oncotargets Ther.* 2015;9: 139–148.
27. Liu J, Wu J, Zhou L, et al. ZD6474, a new treatment strategy for human osteosarcoma, and its potential synergistic effect with celecoxib. *Oncotarget.* 2015;6(25):21341–21352.
28. Pahl JH, Ruslan SE, Buddingh EP, et al. Anti-EGFR antibody cetuximab enhances the cytolytic activity of natural killer cells toward osteosarcoma. *Clin Cancer Res.* 2012;18(2):432–441.
29. Lee JA, Ko Y, Kim DH, et al. Epidermal growth factor receptor: is it a feasible target for the treatment of osteosarcoma? *Cancer Res Treat.* 2012;44(3):202–209.

Supplementary material

Normal	Osteosarcoma	Figure 1A	Figure 1B	Normal	Osteosarcoma	Figure 1D	Normal	Osteosarcoma	Figure 1E	Months	Low
0.89264	1.287677			0.914439	1.287677		1.22294	0.679951		10	1
0.893341	1.292582			0.547052	1.292582		1.21759	0.693489		10	1
0.714501	1.269456			0.559035	1.269456		0.96507	0.709257		20	1
0.908894	1.245541			0.566293	1.245541		0.967745	0.718807		20	0
0.952344	1.39122			0.878771	1.39122		0.620011	0.528638		30	1
1.27331	1.383256			0.9557	1.383256		1.5525	0.540717		30	0
0.961454	1.356349			0.586258	1.356349		0.602417	0.545077		40	1
0.802723	1.056747			0.904836	1.056747		0.962395	0.747068		40	0
1.08865	1.241504			0.598183	1.241504		1.319775	0.760767		40	1
1.085146	1.242699			0.604989	1.242699		0.619749	0.769723		50	1
0.988435	1.178989			0.89396	1.178989		0.647695	0.772279		50	0
0.982128	1.186953			0.647136	1.186953		1.224545	0.825179		50	1
1.011211	1.253847			0.660482	1.253847		0.625532	0.84274		50	1
1.421723	1.264996			0.949228	1.264996		1.18977	0.694711		60	1
0.927466	1.126031			0.563421	1.126031		1.00145	0.715028		60	1
0.915202	1.117271			0.479845	1.117271		0.98112	0.605059		60	1
1.258944	1.403165			0.483799	1.403165		0.676345	0.410262		60	0
1.273661	1.390424			0.494849	1.390424		1.58781	0.624801		10	
0.984581	1.107715			0.499672	1.107715		1.398955	0.931148		10	
0.879811	1.116076			0.503777	1.116076		0.914245	0.936549		10	
1.260696	1.394804			0.505216	1.394804		0.655435	0.638442		20	
1.261046	1.378479			0.994307	1.378479		1.592625	0.642712		20	
0.910646	1.108909			0.520192	1.108909		1.194585	0.958148		20	
0.937627	1.268979			0.523277	1.268979		0.659966	0.662207		30	
0.964608	1.399639			0.968642	1.399639		1.429985	0.84887		30	
0.98353	1.302425			1.196997	1.302425		1.43694	0.860516		30	
0.965309	1.29924			0.979677	1.29924		1.64559	0.861154		30	
0.954446	1.240309			0.676534	1.240309		1.64559	0.86386		30	
0.675	1.406749			0.698849	1.241901		1.68625	0.893223		40	
0.933072	1.16784			0.732779	1.241105		1.31282	0.937867		40	
0.912048	1.151515			0.543765	1.401175		1.31603	0.589164		50	
0.933072	1.164256			0.550605	1.411129		1.406445	0.498164		60	
miR-141	EGFR	Figure 2B	Figure 2E			Control			miR-141 mimic		
0.679951	1.287677			EGFR	0.813929	0.740701	0.977996	0.556612	0.483047	0.516434	
0.693489	1.292582					Control			miR-141 mimic		
0.709257	1.269456		Figure 2F	miR-141	0.851926	0.863442	0.885039	1.136019	1.178995	1.121629	
0.718807	1.245541			EGFR	0.923118	0.827449	0.723539	0.486442	0.445099	0.463735	
0.528638	1.39122		Figure 2D			Control			miR-141 mimic		
0.540717	1.383256			EGFR-WT	1	1	1	0.469963	0.368546	0.412558	0.933024
0.545077	1.356349			EGFR-DEL	0.897	0.993	1.121	0.894	1.121	0.965	0.987
0.747068	1.056747		Figure 2I	EGFR	0.818595	0.644859	0.793873	0.943673	0.975999	0.998253	
0.760767	1.241504					Control			miR-141 inhibitor		
0.769723	1.242699					Control			miR-141 inhibitor		
0.772279	1.178989		Figure 2J	miR-141	0.817203	0.800918	0.864295	0.487667	0.484255	0.442202	
0.825179	1.186953			EGFR	0.573	0.584	0.521	0.8096	0.76	0.861309	
0.84274	1.253847		Figure 3A			Control			50 nm miR-141		
0.694711	1.264996			0	0.291423	0.214622	0.239044	0.226611	0.298189	0.278957	0.20711
0.715028	1.126031			12	0.621187	0.612779	0.605093	0.681773	0.602975	0.65269	0.596409
0.605059	1.117271			24	0.97807	0.939948	0.939666	0.974172	0.928994	0.936003	0.652845
0.410262	1.403165			36	1.091807	1.047452	1.026403	1.067699	1.082694	1.06441	0.720475
0.624801	1.390424			48	1.161624	1.158884	1.107145	1.178279	1.186746	1.140675	0.808309
0.931148	1.107715		Figure 3B			Control			50 nm miR-141 in		
0.936549	1.116076			0	0.265225	0.21556	0.220952	0.241902	0.287741	0.208685	0.22074
0.638442	1.394804			12	0.544198	0.555834	0.540096	0.504176	0.508129	0.588894	0.748543
0.642712	1.378479			24	0.613246	0.642409	0.679103	0.659468	0.685794	0.647473	0.867799
0.958148	1.108909			36	0.786112	0.768608	0.743417	0.785384	0.784699	0.717621	0.95349
0.662207	1.268979			48	0.8547	0.884518	0.861967	0.857614	0.813871	0.837501	1.004312
0.84887	1.399639		Figure 3C			Control			miR-141 mimic		
0.860516	1.302425			0	0.190106	0.222629	0.174284	0.188348	0.190985	0.192743	0
0.861154	1.29924			12	0.64367	0.565896	0.659422	0.507533	0.424544	0.467453	12
0.86386	1.240309			24	0.794295	0.93803	1.008912	0.618122	0.675528	0.704522	24
0.893223	1.241901			36	0.945905	0.944921	1.172336	0.739486	0.76848	0.612735	36
0.937867	1.241105			48	0.992176	1.281613	1.049276	0.779566	0.841818	0.740651	48

(Continued)

(Continued)

Normal	Osteosarcoma	Figure 1A	Figure 1B	Normal	Osteosarcoma	Figure 1D	Normal	Osteosarcoma	Figure 1E	Months	Low
0.589164	1.401175		Figure 3D			Control			miR-141 inhibitor		
0.498164	1.411129			0	0.119786	0.118907	0.120665	0.120665	0.125939	0.115391	0
				12	0.52687	0.479154	0.460067	0.630492	0.643988	0.639168	12
				24	0.614495	0.658741	0.629244	0.814616	0.82522	0.875348	24
				36	0.760247	0.716869	0.76632	0.971748	0.973676	0.963072	36
				48	0.785407	0.789745	0.787142	1.005488	1.058508	1.11442	48
Figure 3E			Control			miR-141 mimic			Figure 3F		Control
	EGFR	0.952581	0.988477	0.902963	0.704545	0.779608	0.759491		EGFR	0.726979	0.782508
	Akt	0.67	0.66	0.67	0.65	0.63	0.69		Akt	0.789086	0.909571
	Akt ^{p-Ser473}	0.983	0.89	1.211	0.873	0.673	0.569		Cyclin D1	1.014	1.056
	Cyclin D1	1.02	0.98	0.99	0.589762	0.532143	0.529286				
Figure 3G			Control			miR-141 inhibitor			Figure 3H		Control
	EGFR	0.591473	0.563248	0.590923	0.854514	0.861974	0.882811		EGFR	0.692633	0.666197
	Akt	0.727021	0.660904	0.6017	0.607387	0.765874	0.668041		Akt	0.873571	0.818929
	Akt ^{p-Ser473}	0.397387	0.365874	0.368041	0.787521	0.799621	0.651396		Cyclin D1	0.341181	0.370977
	Cyclin D1	0.388216	0.355483	0.314096	0.838734	0.826269	0.623645				
Figure 4E			Control			miR-141 mimic			Figure 4F		Control
	Caspase3	0.128607	0.160638	0.155549	0.325562	0.354354	0.303111		Caspase3	0.313187	0.302692
	Caspase9	0.30176	0.337598	0.344824	0.767514	0.702331	0.746625		Caspase9	0.431243	0.470823
	PARP	0.224185	0.285448	0.278476	0.135076	0.054632	0.18091		PARP	0.50665	0.57219
	Bcl-2	0.7096	0.76	0.761309	0.576	0.623	0.611		Bcl-2	0.910014	0.953233
	Bax	0.432	0.551	0.489	0.927738	0.93369	0.870238		Bax	0.318	0.413
Figure 4G			Control			miR-141 inhibitor			Figure 4H		Control
	Caspase3	0.812531	0.842333	0.849489	0.349136	0.345846	0.321304		Caspase3	0.432215	0.490568
	Caspase9	0.532029	0.554109	0.536524	0.219695	0.266747	0.213268		Caspase9	0.553957	0.593721
	PARP	0.143508	0.111379	0.15126	0.23368	0.235066	0.268882		PARP	0.204911	0.276249
	Bcl-2	0.336417	0.390374	0.381756	0.931038	0.823712	0.886543		Bcl-2	0.346445	0.377691
	Bax	0.873	0.983	0.657	0.337111	0.34295	0.480704		Bax	0.835	0.738
Figure 5A		Control				miR-141 mimic			Figure 5B	Control	
	99	108	92	78	73	72		109	108	102	128
Figure 5C		Control				miR-141 mimic			Figure 5D	Control	
	109	107	90	88	75	74		112	101	92	125
Figure 5E		Control				miR-141 mimic			Figure 5F	Control	
	MMP2	0.684549	0.694317	0.671346	0.488371	0.446517	0.409487		MMP2	0.623547	0.640708
Figure 5G		Control				miR-141 inhibitor			Figure 5H	Control	
	MMP2	0.69471	0.661028	0.653454	0.899134	0.8881	0.892913		MMP2	0.662223	0.676677
Figure 6A		Control				miR-141 mimic			EGFR-FL+miR-141		
	0	0.18106	0.18834	0.189	0.18441	0.18592	0.17562	0.18106	0.18834	0.189	0.18441
	12	0.34112	0.31804	0.34724	0.35259	0.21848	0.3589	0.34112	0.31804	0.34724	0.45259
	24	0.55394	0.50654	0.54764	0.46889	0.41488	0.35725	0.45394	0.47654	0.54764	0.56889
	36	0.69242	0.66601	0.66385	0.50856	0.47618	0.57085	0.59242	0.56601	0.66385	0.60856
	48	0.79228	0.70507	0.7059	0.64914	0.51405	0.52044	0.69228	0.60507	0.6059	0.84914
		Control				miR-141 mimic			EGFR-FL+miR-141		
	0	0.20046	0.279118	0.240864	0.242906	0.29667	0.298093	0.21754	0.29595	0.227179	0.290278
	12	0.50701	0.48623	0.51252	0.51733	0.39663	0.42301	0.50701	0.48623	0.51252	0.60733
	24	0.69854	0.65589	0.69288	0.592	0.57339	0.52153	0.60854	0.62889	0.62288	0.712
	36	0.72318	0.79941	0.79747	0.65771	0.62857	0.71377	0.73318	0.70941	0.79747	0.74771
	48	0.81305	0.83456	0.73531	0.78422	0.66265	0.6684	0.82305	0.74456	0.74531	0.87422
Figure 6D		Control				miR-141 mimic			EGFR-FL+miR-141		EGFR-DEL+miR-141
	89	87	99	67	65	53	78	73	67	98	88
Figure 6E		Control				miR-141 mimic			EGFR-FL+miR-141		
	EGFR	0.856307	0.73761	0.761265	0.465596	0.45697	0.480707	0.656307	0.63761	0.661265	0.846596
	Akt ^{p-Ser473}	0.728689	0.790297	0.723591	0.532804	0.516049	0.569373	0.647689	0.665997	0.660591	0.840804
	Akt	0.850858	0.819466	0.81772	0.891937	0.865709	0.84239	0.859858	0.838466	0.81772	0.872937
	Cyclin D1	0.831747	0.751105	0.751779	0.6058	0.596381	0.501556	0.740747	0.770105	0.670779	0.9868
	Bcl-2	0.72318	0.79941	0.79747	0.55771	0.42857	0.41377	0.53318	0.60941	0.59747	0.94771
	Bax	0.41305	0.43456	0.43531	0.78422	0.66265	0.6684	0.52305	0.54456	0.54531	0.37422
	MMP2	0.72318	0.6941	0.79747	0.45771	0.42857	0.41377	0.53318	0.50941	0.59747	0.74771

Abbreviations: EGFR, epidermal growth factor receptor; MMP, matrix metalloproteinase; in, inhibitor.

High	Figure 1F		hFOB1.19		MG63	HOS									
	Control		miR-141 inhibitor												
0.211055	0.285299	0.26733	0.287883	0.295171	0.224493										
0.409888	0.49167	0.403157	0.375692	0.305209	0.311979										
0.523221	0.580987	0.580074	0.407581	0.475779	0.467966										
0.617034	0.644146	0.68313	0.544678	0.564871	0.543867										
0.787204	0.709196	0.779054	0.656273	0.652792	0.612581										
	miR-141 mimic														
0.769223	0.514093	0.520124	0.529782												
0.906979	0.780731	0.906114	0.814469												
1.061	0.876491	0.82482	0.95689												
	miR-141 inhibitor														
0.629849	0.802612	0.898734	0.826594												
0.77	0.766429	0.843571	0.763929												
0.329199	0.665037	0.777423	0.857121												
	miR-141 mimic														
0.332229	0.613433	0.68075	0.605028												
0.421942	0.787769	0.748468	0.712544												
0.507886	0.261598	0.247511	0.215123												
0.79992	0.477	0.388	0.356												
0.452	0.7096	0.76	0.761309												
	miR-141 inhibitor														
0.402993	0.259873	0.227101	0.281723												
0.538475	0.30582	0.397975	0.341285												
0.242776	0.494545	0.443474	0.46951												
0.301652	0.678	0.772	0.801												
0.901	0.38875	0.415119	0.363929												
miR-141 inhibitor															
123	142														
miR-141 inhibitor															
127	122														
	miR-141 mimic														
0.669935	0.42933	0.445463	0.491881												
	miR-141 inhibitor														
0.663598	0.805941	0.881052	0.845455												
EGFR-DEL+miR-141															
0.18592	0.17562														
0.41848	0.3589														
0.61488	0.65725														
0.77618	0.77085														
0.81405	0.72044														
EGFR-DEL+miR-141															
0.290155	0.225673														
0.59663	0.52301														
0.66339	0.70153														
0.80857	0.80377														
0.80265	0.8484														
94															
EGFR-DEL+miR-141		Figure 6F		Control	miR-141 mimic		EGFR-FL+miR-141		EGFR-DEL+miR-141						
0.85697	0.870707		EGFR	0.756307	0.73761	0.761265	0.465596	0.35697	0.480707	0.656307	0.53761	0.661265	0.746596	0.85697	0.870707
0.897049	0.831373		Akt	0.850858	0.719466	0.81772	0.891937	0.765709	0.84239	0.859858	0.738466	0.81772	0.772937	0.827709	0.82339
0.827709	0.82339		Cyclin D1	0.731747	0.751105	0.751779	0.6058	0.496381	0.501556	0.740747	0.670105	0.670779	0.8868	0.922381	0.963556
0.922381	0.963556		Bcl-2	0.62318	0.79941	0.79747	0.45771	0.42857	0.41377	0.53318	0.60941	0.49747	0.84771	0.80857	0.80377
0.80857	0.80377		Bax	0.41305	0.33456	0.43531	0.78422	0.56265	0.6684	0.52305	0.54456	0.44531	0.37422	0.30265	0.3484
0.30265	0.3484		MMP2	0.731747	0.651105	0.751779	0.5058	0.496381	0.501556	0.540747	0.670105	0.670779	0.6868	0.922381	0.963556
0.80857	0.80377														

OncoTargets and Therapy**Dovepress****Publish your work in this journal**

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on

patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <http://www.dovepress.com/oncotargets-and-therapy-journal>